Version October 2024
The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Adverse reactions reported in adults.
>10%: Hepatic: Increased serum transaminases (including increased serum alanine aminotransferase, increased serum aspartate aminotransferase)
There are no contraindications listed in the manufacturer's labeling.
Each 1 mL of product contains fidanacogene elaparvovec-dzkt 1 x 1013 vg.
Excipient information presented when available (limited, particularly for generics); consult specific product labeling.
Suspension Therapy Pack, Intravenous [preservative free]:
Beqvez: Fidanacogene elaparvovec-dzkt 4 x 1 mL (1 ea); Fidanacogene elaparvovec-dzkt 5 x 1 mL (1 ea); Fidanacogene elaparvovec-dzkt 6 x 1 mL (1 ea); Fidanacogene elaparvovec-dzkt 7 x 1 mL (1 ea)
No
Suspension Therapy Pack (Beqvez Intravenous)
4 x 1 mL (per each): $0.00
5 x 1 mL (per each): $0.00
6 x 1 mL (per each): $0.00
7 x 1 mL (per each): $0.00
Disclaimer: A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer. Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions. In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data. Pricing data is updated monthly.
Hemophilia B, moderate to severe: Treatment of moderate to severe hemophilia B (congenital factor IX deficiency) in adults who currently use factor IX prophylaxis therapy or have current or historical life-threatening hemorrhage or have repeated, serious spontaneous bleeding episodes and do not have neutralizing antibodies to adeno-associated virus serotype Rh74var (AAVRh74var) capsid as detected by an FDA-approved test.
None known.
There are no known significant interactions.
آیا می خواهید مدیلیب را به صفحه اصلی خود اضافه کنید؟
